The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study


Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Aim(s): The main objective was to evaluate Rb expression by immunohistochemistry (IHC) as a predictive and/or prognostic factor in patients with G3 NEC. Secondary objectives were to evaluate predictive factors of response, progression-free (PFS) and overall survival (OS) under first line platinum/etoposide (PE).

Materials and methods: Inclusion criteria were: G3NEC whatever the primary and stage, first line treatment with PE and available tumor samples. G3NET were excluded. We report monocentric data from 63 evaluable metastatic patients (pts).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,

To read the full abstract, please log into your ENETS Member account.